Accelerated titration designs for phase I clinical trials in oncology.
暂无分享,去创建一个
R Simon | R. Simon | M. Christian | B. Freidlin | L. Rubinstein | S. Arbuck | J. Collins | S G Arbuck | B Freidlin | M C Christian | J. Collins | L Rubinstein | R. Simon | J Collins
[1] B. Carlin,et al. Adaptive design improvements in the continual reassessment method for phase I studies. , 1999, Statistics in medicine.
[2] S. Piantadosi,et al. Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.
[3] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[4] S. Møller,et al. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.
[5] M. Ratain,et al. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. , 1994, Journal of the National Cancer Institute.
[6] M J Ratain,et al. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. , 1993, Journal of the National Cancer Institute.
[7] M J Ratain,et al. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. , 1993, Journal of the National Cancer Institute.
[8] L B Sheiner,et al. A simulation study comparing designs for dose ranging. , 1991, Statistics in medicine.
[9] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[10] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[11] L. Sheiner,et al. Study designs for dose‐ranging , 1989, Clinical pharmacology and therapeutics.
[12] A. Gould,et al. The analysis of titration studies in phase III clinical trials. , 1989, Statistics in medicine.
[13] C. Chuang. The analysis of a titration study. , 1987, Statistics in medicine.
[14] R. Wittes,et al. Therapeutic response in phase I trials of antineoplastic agents. , 1986, Cancer treatment reports.
[15] B. Chabner,et al. Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.
[16] T. Chou,et al. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. , 2005, European journal of biochemistry.
[17] S. Zacks,et al. Sequential Search of an Optimal Dosage, I , 1973 .
[18] L. Goodman,et al. THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .